小剂量地西他滨联合阿糖胞苷治疗骨髓增生异常综合征临床观察被引量：4

Clinical observation of low-dose decitabine combined with cytarabine in the treatment of myelodysplastic syndromes

导出

摘要目的：探讨小剂量地西他滨联合阿糖胞苷治疗骨髓增生异常综合征（MDS）的临床疗效和安全性。方法收集2012年1月至2015年1月接受小剂量地西他滨联合阿糖胞苷方案治疗的15例MDS 患者临床资料，评价其疗效和不良反应。结果15例患者中完全缓解4例，部分缓解5例，稳定、进展和无效6例，总有效率为60.0%（9／15）。总感染率为40.0%（6／15），其中肺部感染率为26.7%（4／15），Ⅲ～Ⅳ度骨髓抑制率为73.3%（11／15）。患者经积极抗感染、刺激造血及输血等支持治疗后感染得到控制。15例患者均无严重肝损害，未出现化疗相关死亡。结论小剂量地西他滨单药联合阿糖胞苷方案治疗 MDS 有一定疗效，可延缓疾病进展，患者能耐受化疗不良反应，无化疗相关死亡。 Objective To explore the clinical efficacy and safety of low-dose decitabine combined with cytarabine for myelodysplastic syndromes （MDS）. Methods Clinical data of 15 patients with MDS who took the therapeutic regimen with decitabine combined with cytarabine were collected from January 2012 to January 2015. The clinical efficacy and adverse effects were assessed. Results Among the 15 patients, 4 cases were complete remission （CR）, 5 cases were partial remission （PR） and 6 cases were stable disease （SD） and progressive disease （PD）. The total effective rate was 60.0 % （9/15）. Grade Ⅲ-Ⅳ bone marrow depression occurred in 11 cases with incidence rate of 73.3 % （11/15）, and the total incidence rate of infection was 40.0 % （6/15）, including lung infection of 26.7 % （4/15）. All the infections were controlled after active supportive treatment and anti-infection therapy. No patient died of chemotherapy. Conclusions Low-dose decitabine combined with cytarabine can effectively treat MDS and delay the progress of disease. The patients can tolerate the adverse effects in chemotherapy with a low mortality rate.

作者黄达永付丽魏娜王晶石沈晶吴林王旖旎崔华王昭

机构地区首都医科大学附属北京友谊医院血液科

出处《白血病．淋巴瘤》 CAS 2016年第7期406-408,共3页 Journal of Leukemia & Lymphoma

关键词骨髓增生异常综合征地西他滨阿糖胞苷 Myelodysplastic syndromes Decitabine Cytarabine

分类号 R551.3 [医药卫生—血液循环系统疾病]

引文网络
相关文献

参考文献6

1Huang D, Nagata Y, Grossmann V, et al. BRCC3 mutations in myeloid neoplasms? [J]. Haemalologica, 2015, 100 (8): 1051- 1057. DOI : 10.3324/haematol.2014.111989. S.
2ekeres MA, Cutler C. How we treat higher-risk myelodysplastic syndromes [J]. Blood, 2014, 123 (6): 829-836. DOI:10.1182/ blood-2013-08-496935.
3Itzykson R, Fenaux P. Epigenetics of myelodysp|astic syndromes [J 1. Leukemia, 2014, 28(3): 497-506. DOI: 10.1038/leu.2013.343.
4韩波,王朝晖,邵纬,王九河,洪青,范传波,刘俊玲,田猛,王海霞,乌庆超.地西他滨联合化疗治疗难治复发急性髓系白血病及骨髓增生异常综合征转化白血病的效果观察[J].白血病．淋巴瘤,2014,23(12):733-736. 被引量：14
5Leonard SM, Perry T, Woodman CB, et al. Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia [J]. PLoS One, 2014, 9 (1): e87475. DOI: 10.1371/joumal.pone.0087475.
6高苏,仇惠英,金正明,唐晓文,傅铮铮,马骁,韩悦,陈苏宁,孙爱宁,吴德沛.地西他滨单药及联合半程和全程CAG方案治疗骨髓增生异常综合征和急性髓系白血病疗效观察[J].中华血液学杂志,2014,35(11):961-965. 被引量：73

二级参考文献31

1Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open- label, phase Ⅲ trial of decitabine versus patient choice, with physician advice, of either supportive care or low- dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia [J]. J Clin Oncol, 2012, 30(21 ):2670-2677.
2Yamada K, Furusawa S, Saito K, et al. Concttrrent use of granu- locyte colony-stimulating factor with low-dose cytosine arabino- side and aclarubicin for previously treated acute myelogenous leukemia: a pilot study[J]. Leukemia,1995, 9 ( 1 ): 10-14.
3Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommen- dations of the International Working Group for diagnosis, stan- dardization of response criteria, treatment outcomes, and report- ing standards for therapeutic trials in acute myeloid leukemia EJ]. J Clin Oncol, 2003, 21 (24):4642-4649.
4Cheson BD, Greenberg PL, Bennett JM, et al. Clinical applica- tion and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia[J]. Blood, 2006, 108(2):419-425.
5Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastie syndromes: the alternative dosing for out- patient treatment (ADOPT) trial [J]. J Clin Oncol, 2009, 27(23):3842-3848.
6Chowdhury S, Seropian S, Marks PW. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia [J]. Am J Hematol, 2009, 84 (9) :599-600.
7Scandura JM, Roboz GJ, Moh M, et al. Phase 1 study ofepigen- etic priming with decitabine prior to standard induction chemo- therapy for patients with AML[J]. Blood, 2011, 118(6):1472- 1480.
8Song LX, Xu L, Li X, et al. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia[J]. Ann Hematol, 2012, 91 (12): 1879-1886.
9Qin T, Youssef EM, Jelinek J, et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines IJ]. Clin Cancer Res, 2007, 13( 14):4225-4232.
10Qian S, Duan L. Effect of low-dose cytarabine and aclarubicin in combination with decitabine on the outcome of patients with high-risk myelodysplastic syndromes [G]. 12^th International Symposium on Myelodysplastie Syndromes. Berlin, Germany: Leukemia Research, 2013: S 152-S 153.